Chemical Liability Screening for Biotherapeutic Protein Discovery
Digitalizing mRNA Workflows for Vaccines and Therapeutics
Enabling MS-Based MAM in QC Through a Robust New Peak Detection Workflow
X-Omics Platform Accelerates Precision Medicine
Journey to Validated NGS In-House
Japan: DX Platform for Increasing Success Rates in Pharma R&D
What’s New in Genedata Screener 2025
Accelerating RNA Drug Discovery with Automated Data Analysis
Enhancing Biotherapeutic Data Management at Zoetis
Full-Circle MS Workflow Automation
Reducing Oncology Drug Failures with Organoid Models and Multi-Omics
Screening on Autopilot — Assay Cascades by Digitalizing Workflows
Driving Biomarker Research Efficiency
Deploying a Fully Integrated Biologics Database
Sanofi’s Large Molecules Research Data Platform
Unlocking Insights from Long Read-Sequencing for Product QC
Automating Gene Therapy Long-Read Based QC Assays
Safety of Human Cell Products: The Value of NGS
MS-Based Profiling, Fingerprinting, & Speciation of Polymeric Excipients
Automated & Interactional Ion Channel Data Analysis
Robust NGS Pipelines for Virus Detection
MS-based Analytics for the Investigation of In Vivo Biotransformation of Biotherapeutics
Overcoming the Challenges of Disulfide Bond Characterization
Japan: What Digital Platforms Can Bring to Biomarker Researchers
AbbVie Streamlines Multi-Specifics Biologics Discovery and Engineering
Fully Automated NGS Assays in a GMP Environment
Considerations for a GMP-Compliant NGS Method
Nanopore Sequencing for AAV Vectors & DNA Impurities
Selector Playbooks: Automation of NGS Workflows
NGS Implementation for Adventitious Virus Detection
What’s New in Genedata Screener 21
Advancing Early Cancer Immunotherapy Trials
Genedata Selector Open Forum 8: Introduction by Astellas
GMP-Compliant Viral Risk Assessment of Live Vaccines
NGS as a Multi-Attribute Method for Cell Therapy Production QC
E2E Data Platform to Digitalize & Automate Single-Domain Antibody (sdAbs) R&D
Digitalizing Across mAbs, Bispecifics, ADCs
Japan: JBA "NGS for CQA Assessment of Biological Products"
Process Changes Impacting AAV CQAs Assessed with NGS
NGS as MAM to Support AAV Gene Therapy Production
